Tag: funding

15 articles

Market Moves

Chinese startup Junrou raises nearly RMB 100 million for brain electrodes steered by magnets

Junrou Technology, founded in 2025 by Liu Zhiyuan of the Shenzhen Institutes of Advanced Technology, has closed an angel-plus round of nearly RMB 100 million led by Shunwei Capital, with GL Ventures, humanoid robot maker AgiBot and Nansha Qisheng following. The company is commercialising NeuroWorm, a soft fibre electrode published in Nature in September 2025 that can be steered through tissue by an external magnet. It plans an investigator-initiated clinical study in 2027, starting with epilepsy and depression, and has also developed electronic skin for robot hands.

Nov 12

Market Moves

China BCI funding and IPO tracker 2026

The 2026 financing rounds and listing steps by Chinese brain-computer interface companies verified by InsideBCI, from BrainCo's RMB 2 billion round to Neuracle's STAR Market application, with amounts, lead investors and sources. Updated as new rounds are announced.

Nov 8

Market Moves

Three Chinese BCI companies raised RMB 1.66 billion in eight days

NeuroXess, Nanochap and Shanghai's Zhudong Technology announced rounds totalling RMB 1.664 billion between 28 October and 4 November 2026, with state-backed funds among the investors, while StairMed filed for A-share pre-listing tutoring. The 'over RMB 3 billion in a week' figure in Chinese coverage adds StairMed's financing since July.

Nov 5

Market Moves

Chinese vision-implant maker Nanochap raises RMB 500 million

Hangzhou-based Nanochap Electronics said on 3 November 2026 that it had closed a RMB 500 million Series C+ round led by Gaorong Ventures, its second round of 2026, bringing its total funding to RMB 1 billion. The company is running a registration trial of a 320-channel retinal implant that it says has been placed in three blind patients.

Nov 4

Market Moves

NeuroXess raises RMB 700 million for its brain implant

Shanghai brain-computer interface company NeuroXess announced a RMB 700 million Series B round on 28 October 2026, co-led by SDIC Juli, Shenzhen Capital Group and Qinzhi Capital and described by 36Kr as dominated overall by state capital. The money will fund the multicentre registration trial of its implant for people with quadriplegia, a factory in Jiangxi and next-generation products.

Oct 29

Market Moves

CereGate raises Series C for a Parkinson's walking therapy

CereGate, a Munich company developing a therapy for freezing of gait in Parkinson's disease that runs on Boston Scientific deep brain stimulation implants, said on 14 October 2026 that an unnamed US medtech company had led its Series C. CereGate did not disclose the amount or its valuation. Its US trial began in April 2022, with main data collection due to finish in June 2027.

Oct 15

Market Moves

Sabi raises $50 million for a brain-sensing baseball cap

Khosla Ventures has led a $50 million seed round in Sabi, a California startup building a baseball cap meant to turn imagined words and trained mental commands into text and instructions for AI assistants. Accel, Initialized Capital, former OpenAI chief product officer Kevin Weil, DST Global, Collaborative Fund and Ascend also invested, Sabi announced on 9 October 2026. Forbes put the valuation at $600 million, citing a person familiar with the deal. The cap is designed to read brain signals through hair with sensors built around a custom EEG chip, and to decode them with a model Sabi says was trained on more than 100,000 hours of labelled recordings. In April, Sabi said its first product would be a beanie available by the end of 2026. The cap will now debut as an early prototype at CES in January, and Forbes reported that it will not be available until 2027. Sabi has named no price and published no peer-reviewed results, and its only accuracy figure, up to 77 per cent, comes from a wired laboratory prototype.

Oct 11

Market Moves

Bridge Neurotech raises $13.5 million to build a brain-computer interface without surgery

Bridge Neurotech, a Silicon Valley start-up founded in 2026 by Will Biederman, came out of stealth on 6 October with $13.5 million from General Catalyst, reMind Capital, Sunflower Capital, Scott Sandell and others to build a wearable brain-computer interface that images brain activity with functional ultrasound through the skull. It has signed a multi-year research and development agreement to license Butterfly Network's Ultrasound-on-Chip technology, with payments for technology access and development milestones and commitments to buy Butterfly hardware; the value was not disclosed. Biederman co-founded the ultrasound research group Forest Neurotech, which signed a five-year, $20 million co-development deal with Butterfly in 2023. Forest's other two co-founders, Sumner Norman and Tyson Aflalo, went on to co-found Merge Labs, which signed its own Butterfly licensing deal on 1 September. Bridge's first research study, which is observational, is enrolling healthy adults and adults whose skulls were repaired with PEEK or Longeviti implants in Redwood City, California.

Oct 8

Market Moves

MintNeuro raises $5 million to supply purpose-built chips to neural device makers

MintNeuro, a London semiconductor company spun out of Imperial College London, announced a $5 million round on 7 October 2026 led by Odyssey Ventures, with 33East, JSK Investments and Alumni Ventures joining and Empirical Ventures, Jumpspace Ventures and other early investors investing again. It designs modular chips for neural sensing, signal processing and stimulation that device makers can build on in place of adapted general-purpose components or years of custom chip design. Its partners include Motif Neurotech, which announced a multi-year chip supply agreement with MintNeuro on 30 April for its depression implant, and Amber Therapeutics, whose co-founder Tim Denison chairs MintNeuro. The money will fund product launches, delivery of pre-release chips to partners, a larger team and a stronger US presence. MintNeuro's last disclosed equity round was £1 million in November 2024.

Oct 8

Market Moves

Science Corp Raises $230 Million to Commercialise PRIMA Retinal Implant

Science Corporation closes a $230 million Series C with participation from Khosla Ventures, Lightspeed Venture Partners and Y Combinator, at a reported post-money valuation of $1.5 billion, as it targets a European launch of the PRIMA vision-restoration implant by mid-2026.

Mar 6